Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.
Höglund M, Sandin F, Hellström K, Björeman M, Björkholm M, Brune M, Dreimane A, Ekblom M, Lehmann S, Ljungman P, Malm C, Markevärn B, Myhr-Eriksson K, Ohm L, Olsson-Strömberg U, Själander A, Wadenvik H, Simonsson B, Stenke L, Richter J. Höglund M, et al. Among authors: simonsson b. Blood. 2013 Aug 15;122(7):1284-92. doi: 10.1182/blood-2013-04-495598. Epub 2013 Jul 10. Blood. 2013. PMID: 23843494 Free PMC article.
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
Simonsson B, Gedde-Dahl T, Markevärn B, Remes K, Stentoft J, Almqvist A, Björeman M, Flogegård M, Koskenvesa P, Lindblom A, Malm C, Mustjoki S, Myhr-Eriksson K, Ohm L, Räsänen A, Sinisalo M, Själander A, Strömberg U, Bjerrum OW, Ehrencrona H, Gruber F, Kairisto V, Olsson K, Sandin F, Nagler A, Nielsen JL, Hjorth-Hansen H, Porkka K; Nordic CML Study Group. Simonsson B, et al. Blood. 2011 Sep 22;118(12):3228-35. doi: 10.1182/blood-2011-02-336685. Epub 2011 Jun 17. Blood. 2011. PMID: 21685374 Free article. Clinical Trial.
Epidemiology of chronic myeloid leukaemia: an update.
Höglund M, Sandin F, Simonsson B. Höglund M, et al. Among authors: simonsson b. Ann Hematol. 2015 Apr;94 Suppl 2:S241-7. doi: 10.1007/s00277-015-2314-2. Epub 2015 Mar 27. Ann Hematol. 2015. PMID: 25814090 Review.
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.
Axdorph U, Stenke L, Grimfors G, Carneskog J, Hansen J, Linder O, Ljungman P, Löfvenberg E, Malm C, Simonsson B, Turesson I, Vilén L, Udén AM, Björkholm M; Swedish CML Group. Axdorph U, et al. Among authors: simonsson b. Br J Haematol. 2002 Sep;118(4):1048-54. doi: 10.1046/j.1365-2141.2002.03765.x. Br J Haematol. 2002. PMID: 12199784 Free article. Clinical Trial.
Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival.
Olsson-Strömberg U, Simonsson B, Ahlgren T, Björkholm M, Carlsson K, Gahrton G, Hast R, Löfvenberg E, Linder O, Ljungman P, Malm C, Paul C, Rödjer S, Turesson I, Udén AM, Wahlin A, Killander A, Wadman B, Westin J, Vikrot O, Zettervall O, Oberg G; Swedish CML Study Group. Olsson-Strömberg U, et al. Among authors: simonsson b. Hematol J. 2004;5(6):462-6. doi: 10.1038/sj.thj.6200552. Hematol J. 2004. PMID: 15570285 Clinical Trial.
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up.
Simonsson B, Oberg G, Bjoreman M, Bjorkholm M, Carneskog J, Karlsson K, Gahrton G, Grimfors G, Hast R, Karle H, Linder O, Ljungman P, Nielsen JL, Nilsson J, Lofvenberg E, Malm C, Olsson K, Olsson-Stromberg U, Paul C, Stenke L, Stentoft J, Turesson I, Udén AM, Wahlin A, Vilén L, Weis-Bjerrum O. Simonsson B, et al. Acta Haematol. 2005;113(3):155-62. doi: 10.1159/000084445. Acta Haematol. 2005. PMID: 15870485 Clinical Trial.
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.
Olsson-Strömberg U, Höglund M, Björkholm M, Braide I, Carlson K, Gahrton G, Grimfors G, Hast R, Lerner R, Linder O, Ljungman P, Löfvenberg E, Malm C, Nilsson PG, Paul C, Rödjer S, Stenke L, Tidefeldt U, Turesson I, Uden AM, Wahlin A, Vilen L, Winqvist I, Zettervall O, Oberg G, Simonsson B. Olsson-Strömberg U, et al. Among authors: simonsson b. Leuk Lymphoma. 2006 Sep;47(9):1768-73. doi: 10.1080/10428190600611117. Leuk Lymphoma. 2006. PMID: 17064986
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Hjorth-Hansen H, Stenke L, Söderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, Gjertsen BT, Höglund M, Koskenvesa P, Lotfi K, Majeed W, Markevärn B, Ohm L, Olsson-Strömberg U, Remes K, Suominen M, Simonsson B, Porkka K, Mustjoki S, Richter J; Nordic CML Study Group. Hjorth-Hansen H, et al. Among authors: simonsson b. Eur J Haematol. 2015 Mar;94(3):243-50. doi: 10.1111/ejh.12423. Epub 2014 Sep 13. Eur J Haematol. 2015. PMID: 25082346 Free PMC article. Clinical Trial.
293 results